[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595293":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":29,"responsibleParty":43,"collaborators":10,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":10,"maxAge":10,"enrollmentInfo":52,"targetDuration":10,"studyType":55,"phases":10,"briefSummary":56,"conditions":57,"keywords":74,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Metastatic breast cancer patients underwent tumor biopsy in a metastatic site",null,"A cohort of patients with metastatic breast cancer underwent a liver, lung, pleural or bone biopsy in the metastatic setting at INT with available imaging (CT scan and\u002For PET-FdG scan), performed from 01Jan2005 to 01Jan2024. A subgroup of this cohort is treated with Trastuzumab Deruxtecan.",[13],"Drug: Trastuzumab deruxtecan (DS-8201a)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Trastuzumab deruxtecan (DS-8201a)","A subgroup of the study cohort treated with Trastuzumab Deruxtecan in the metastatic setting",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Claudio Vernieri, MD, PhD","CONTACT","+390223903066","claudio.vernieri@istitutotumori.mi.it",{"name":27,"role":23,"phone":24,"phoneExt":10,"email":28},"Leonardo Provenzano, MD","leonardo.provenzano@istitutotumori.mi.it",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":10},"Fondazione IRCCS Istituto Nazionale Tumori","RECRUITING","Milan","20133","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],9.18951,45.46427,{"lat":41,"lon":40},{"type":44,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100595293",false,"NCT07030569","RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study","RADIOSPHER2","Inclusion Criteria:\n\n* Patients with metastatic breast cancer underwent a liver, lung, pleural or bone biopsy in the metastatic setting, performed from 01Jan2005 to 01Jan2024.\n\nExclusion Criteria:\n\n* Not available imaging (CT scan and\u002For PET-FdG scan) in the three months before the biopsy or before the last previous treatment interruption;\n* Unknown HER2 status;\n* Node, soft tissue or other visceral as biopsy site.","ALL",{"count":53,"type":54},500,"ESTIMATED","OBSERVATIONAL","RADIOSPHER2 study is a monocentric, retrospective, observational study aiming at identifying a radiomics signature able to predict HER2 expression (0 vs low vs overexpression) and trastuzumab deruxtecan efficacy in metastatic breast cancer patients. The study also encompasses translational analyses and inter-modal correlations in order to provide novel insights about HER2 spatial and temporal heterogeneity, at the macroscopic and microscopic levels.",[58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73],"Radiomic","Radiomics","Breast Cancer Metastatic","Breast Cancer Stage IV","Breast Carcinoma","Breast Neoplasms","Breast Cancer","Breast Cancer With Bone Metastasis","Breast Cancer With Metastatic Bone Disease","Trastuzumab","HER2","HER2 + Breast Cancer","HER2 Positive Breast Carcinoma","HER2-positive Breast Cancer","Her2\u002FNeu Positive Advanced Solid Tumors","HER2\u002FNeu-positive Breast Cancer",[59,75,76,77,78],"HER2 expression","Trastuzumab Deruxtecan","Pathomics","HER2 heterogeneity","2025-06-12",{"date":81,"type":82},"2025-06-22","ACTUAL",{"date":84,"type":82},"2024-02-01",{"date":86,"type":54},"2027-01-01",{"name":5,"class":6},1]